Browsing Tag
Topical Immunotherapy
1 post
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.